GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology firm creating a novel method to immunotherapy designed to orchestrate a focused immune response by directing the operate of antigen-specific T cells, at this time introduced that Kristi Jones, Chief Executive Officer, will current at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET.
The webcast will probably be accessible on the Investor Relations web page of NexImmune’s web site at Events and Presentations | NexImmune, Inc. A replay of the presentation will probably be obtainable at the identical location for 30 days following the convention.
About NexImmune
NexImmune is a clinical-stage biotechnology firm creating a novel method to immunotherapy designed to make use of the physique’s personal T cells to generate a selected, potent, and sturdy immune response.
NexImmune’s lead packages, NEXI-001, NEXI-002 and NEXI-003, are in Phase 1/2 medical trials for the therapy of relapsed AML after allogeneic stem cell transplantation, a number of myeloma refractory to 3 or extra prior traces of remedy and HPV-related cancers, respectively. NexImmune can be creating AIM nanoparticle constructs and modalities for potential medical analysis in oncology and in illness areas exterior of oncology, together with autoimmune problems and infectious illness.
The spine of NexImmune’s method is a proprietary Artificial Immune Modulation (AIM™) nanoparticle know-how platform. The AIM know-how permits NexImmune to assemble nanoparticles that operate as artificial dendritic cells able to directing a selected T cell-mediated immune response. AIM constructed nanoparticles make use of pure biology to have interaction, activate and develop endogenous T cells in ways in which mix anti-tumor attributes of antigen-specific precision, efficiency and long-term persistence with diminished potential for off-target toxicities.
For extra info, go to www.neximmune.com.
Contacts
Investors:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
[email protected]
